A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 590 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Woman Finds Out She Has Breast Cancer From Museum Photo Booth November 1, 2019 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 Load more HOT NEWS Test Detects Early Signs of Remaining Cancer in Kids Treated for... Spotlight On: Occupational Therapists in Cancer Care Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... COVID-19 Vaccine: Distribution and Administration
